FDA Determines Regulatory Review Period for Pfizer's PROMACTA

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Pfizer's PROMACTA, a human drug product, as required by law, following a patent extension application submitted to the US Department of Commerce.